CTOs on the Move


 
Tripos, L.P. is a Saint Louis, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.tripos.com
  • 1699 S Hanley Rd
    Saint Louis, MO USA 63144
  • Phone: 314.647.1099

Executives

Name Title Contact Details

Similar Companies

Atmofizer

The world’s most innovative and effective clean air technology against harmful ultra fine particles incl. COVID-19. Developed in Germany, assembled in the US.

Celmatix

Founded in 2009, Celmatix is a personalized medicine company focused on fertility and women’s health. Our technology-enabled products empower people, through better data, to dramatically improve their chances of conceiving.

GPB Scientific

GPB Scientific is transforming the process of purifying and enriching cells for cell therapy production. Reliable cell recovery and expansion are fundamental to the successful scale up of CAR-T or any therapeutic cell manufacturing process. GPB has developed a high-throughput, automatable, microfluidic closed-system for leukapheresis sample preparation and downstream processing of cells for CAR-T and other cell therapy production. This breakthrough reduces cell losses and skill-intensive manual steps.

CalciMedica

CalciMedica is a privately-held, clinical stage biotechnology company focused on CRAC channel drug discovery and development for the treatment of acute and chronic inflammatory diseases.

Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression. Our integrated epigenetics platform enables us to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. We are able to target a broad variety of epigenetic regulators using our platform and have generated development candidates acting against distinct classes of those regulators.